<--- Back to Details
First PageDocument Content
Boehringer Ingelheim / Mylan / IMS Health / Actavis / Novartis / AstraZeneca / Pharmaceutical sciences / Pharmaceutical drug / Pharmaceutical industry / Pharmacology / Business
Date: 2014-03-20 09:09:11
Boehringer Ingelheim
Mylan
IMS Health
Actavis
Novartis
AstraZeneca
Pharmaceutical sciences
Pharmaceutical drug
Pharmaceutical industry
Pharmacology
Business

` TOP 20 GLOBAL CORPORATIONS 2013

Add to Reading List

Source URL: www.imshealth.com

Download Document from Source Website

File Size: 67,70 KB

Share Document on Facebook

Similar Documents

Mylan Agrees to Pay $465 Million in Restitution to Resolve False Claims Allegations The National Association of Medicaid Fraud Control units announced on August 17, 2017 that an agreement has been reached to settle alleg

DocID: 1uUDJ - View Document

Filed on behalf of: Mylan Pharmaceuticals Inc. By: Steven W. Parmelee Michael T. Rosato Jad A. Mills WILSON SONSINI GOODRICH & ROSATI

DocID: 1trJa - View Document

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD MYLAN PHARMACEUTICALS INC., Petitioner v. SHIRE LABORATORIES, INC.,

DocID: 1tqnl - View Document

Paper No. ____ Filed: November 22, 2016 Filed on behalf of: Mylan Pharmaceuticals Inc. By: Steven W. Parmelee () Michael T. Rosato () Jad A. Mills ()

DocID: 1tpON - View Document

Paper No. ____ Filed: May 25, 2016 Filed on behalf of: Mylan Pharmaceuticals Inc. By: Steven W. Parmelee Michael T. Rosato Jad A. Mills

DocID: 1tkI9 - View Document